Stockscreener 앱 받기
0.40%
시장 영업 전:
전일 마감가:
$351.43
열려 있는:
$350.06
하루 거래량:
2.33M
Relative Volume:
0.87
시가총액:
$190.42B
수익:
$37.30B
순이익/손실:
$7.80B
주가수익비율:
24.54
EPS:
14.3793
순현금흐름:
$8.60B
1주 성능:
+4.51%
1개월 성능:
+3.98%
6개월 성능:
+5.65%
1년 성능:
+25.85%
1일 변동 폭
$350.06
$359.10
1주일 범위
$337.60
$359.10
52주 변동 폭
$269.77
$391.29
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
352.82 | 189.67B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,127.69 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
244.88 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
243.14 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
125.45 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.12 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Hold |
| 2026-03-10 | 개시 | Jefferies | Hold |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In - GuruFocus
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked - marketscreener.com
Amgen faces EU withdrawal of Tavneos (AMGN:NASDAQ) - Seeking Alpha
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential - Insider Monkey
Amgen highlights obesity pipeline progress, shares track pharma peers - Ad-hoc-news.de
EMA recommends revoking marketing authorisation for Amgen's rare-disease drug - Reuters
Amgen clears key resistance level, shares range between support and new highs - Ad-hoc-news.de
Price to earnings forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen reports new biosimilar data, shares in focus among healthcare peers - Ad-hoc-news.de
Amgen Inc. Actuals & Estimates (BMV:AMGN) - TradingView
Inside FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Amgen’s Stock Is Down 10% From Its Highs: The $10 Billion Obesity Drug Bet That Could Define the Next Decade - TIKR.com
Amgen raises lower end of 2026 EPS target, shares stay in focus on NASDAQ - Ad-hoc-news.de
Amgen clears new 2026 high, shares extend biotech sector gains - Ad-hoc-news.de
Amgen dividend confirmed and capital plan detailed, shares under steady Wall Street scrutiny - Ad-hoc-news.de
AMGN Faces Market Scrutiny Over Data Integrity Issues - GuruFocus
Inside the FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Amgen Inc. Stock 12‑Month Price Target Cut to $350.22 - TradingView
Willful Patent Verdict and Possible Treble Damages Could Be A Game Changer For Amgen (AMGN) - simplywall.st
IgG4-RD: From Diagnostic Delays to Collective Action in Rare Disease Care - Amgen
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update - Yahoo Finance
Amgen lifts 2026 revenue outlook, shares trade in a tight NASDAQ range - Ad-hoc-news.de
Kyprolis from Amgen Inc.once-weekly regimen reshapes myeloma routine - Ad-hoc-news.de
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Globe and Mail
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen (AMGN) Stock Could Be 2.1% Undervalued After Patent Verdict - simplywall.st
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story? - The Globe and Mail
(AMGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Update, Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de
Amgen patent verdict reshapes risk picture, shares hold near recent highs - AD HOC NEWS
Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs Trade Ideas — BCBA:AMGN.CI - TradingView
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de
Tezspire from Amgen Inc.severe asthma biologic with shared AstraZeneca launch - AD HOC NEWS
Willful Patent Infringement Verdict Might Change The Case For Investing In Amgen (AMGN) - Yahoo Finance
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen opens the week with upcoming catalysts, shares on Nasdaq - AD HOC NEWS
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals
What a Landmark Real-World Study Reveals About Thyroid Eye Disease - Amgen
Amgen StockWeekly outlook with earnings date and pipeline in view - AD HOC NEWS
Amgen France Names a New Communications Director - marketscreener.com
Why Amgen’s Repatha is quietly reshaping cholesterol therapy - AD HOC NEWS
Amgen Growth Drivers Surge 24 Percent as New Core Takes Over - HarianBasis.co
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Rhode Island - Providence Business News
AMGN News | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen Gives Greater Los Angeles Community an Experience to Remember at FIFA Fan Festival - Amgen
What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? - Yahoo Finance
What If Amgen Stock’s Patent Worries Are Hiding Its Real Growth Engine? - Trefis
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.05%
자본화:
|
볼륨(24시간):